Home › News › Clinical Trials

Evotec Secures USD 2.9 Million Gates Foundation Grant for Foetal Safety Research

Evotec Secures USD 2.9 Million Gates Foundation Grant for Foetal Safety Research

Evotec SE has received a new USD 2.9 million grant from the Gates Foundation to continue developing and applying its human stem cell-based New Approach Methodologies (NAMs) for identifying potential safety risks to foetal development during drug discovery. The funding extends a project launched in 2023 for another three years, enabling researchers involved in global health programmes to continue accessing the technology.

Evotec’s platform uses human induced Pluripotent Stem Cell (hiPSC) models and industrial-scale screening capabilities to assess aspects of human development and identify drug candidates that may pose potential developmental safety risks. The approach is intended to help researchers evaluate possible effects on prenatal development at an earlier stage of drug discovery.

During the initial three-year collaboration, more than 5,000 compounds were screened across nine grantee programmes. The findings demonstrated the platform’s application in generating human-relevant safety data at scale. The development and validation of the platform have also been detailed in a recent bioRxiv preprint.

Dr. Joanna Holbrook, Chief Scientific Officer of Evotec, said early identification of potential safety risks was important for advancing medicines for global health priorities. She noted that the platform enables researchers to assess potential effects on prenatal development using human cells, supporting decisions on which drug candidates to pursue and reducing the likelihood of costly changes later in development.

The platform forms part of Evotec’s broader portfolio of NAMs, which are being developed to support drug discovery and potentially reduce reliance on animal testing. Its capabilities include more than 25 hiPSC-derived cellular models, three-dimensional organoid systems, AI-supported disease modelling and industrial-scale screening technologies.

Evotec’s human iPSC-based teratogenicity hazard identification platform uses in-vitro models, automation and high-content imaging to assess potential developmental safety risks. The company is also integrating machine learning, high-throughput experimentation and genome-scale molecular data to support toxicology prediction across organs.

The extended funding will support continued access to the platform for global health research programmes over the next three years.

More news about: clinical trials | Published by News Bureau | November - 17 - 2026

Last news about this category


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members